Last reviewed · How we verify
Moderna COVID-19 Vaccine
Moderna COVID-19 Vaccine is a Biologic drug developed by National Institute of Allergy and Infectious Diseases (NIAID). It is currently FDA-approved. Also known as: mRNA-1273.
The Moderna COVID-19 Vaccine, developed in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), is currently marketed and holds a significant position in the global vaccine market. A key strength is the protection it offers against COVID-19, supported by robust clinical trial results. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generic manufacturers.
At a glance
| Generic name | Moderna COVID-19 Vaccine |
|---|---|
| Also known as | mRNA-1273 |
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations (PHASE4)
- Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction (PHASE4)
- COVID-19 Breakthrough Infection in Fully Vaccinated People and in People Who Received a Booster Dose
- Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19 (PHASE4)
- A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19) (PHASE4)
- A Study of Modified mRNA Vaccines in Healthy Adults (PHASE1)
- COVID-19 Reactogenicity (PHASE4)
- Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Moderna COVID-19 Vaccine CI brief — competitive landscape report
- Moderna COVID-19 Vaccine updates RSS · CI watch RSS
- National Institute of Allergy and Infectious Diseases (NIAID) portfolio CI
Frequently asked questions about Moderna COVID-19 Vaccine
What is Moderna COVID-19 Vaccine?
Who makes Moderna COVID-19 Vaccine?
Is Moderna COVID-19 Vaccine also known as anything else?
What development phase is Moderna COVID-19 Vaccine in?
Related
- Manufacturer: National Institute of Allergy and Infectious Diseases (NIAID) — full pipeline
- Also known as: mRNA-1273
- Compare: Moderna COVID-19 Vaccine vs similar drugs
- Pricing: Moderna COVID-19 Vaccine cost, discount & access